Recent medical research breakthroughs have generated an unprecedented opportunity for potential new therapies—from genetic modifications to novel proteins—to address unmet needs in many medical areas like blindness and paralysis. At the March 19 WHIPgroup Meetup, Erika Smith of New Haven-based ReNetX Bio, will explore the science behind this new generation of biotech advancements and the opportunities for patients, researchers and investors.
Erika Smith is CEO of ReNetX Bio, a biotech firm that has created first in class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), stroke and glaucoma. Ms. Smith has spent her career advancing entrepreneurs and investing in tech and biotech innovation. She was previously the Director for the $25 Million USD Blavatnik Fund for Innovation at Yale and was part of the leadership team at Yale Entrepreneurial Institute.
By Andrew P. Siuta The next generation of gaming consoles is quickly approaching. Microsoft revealed its new gaming console generation with the Xbox Scarlett and Sony revealed the PlayStation 5. However, with the advances in [Read More…]
New Haven-based online pharmacy Valisure’s CEO David Light spoke at the June 18 session of the WHIPgroup Tech Entrepreneur Meetup at our Stamford offices. David and Valisure are in the news this week. They are [Read More…]
The Defendants in this case were featuring NETZSCH’s trademarks to offer substantially similar goods for sale at trade shows in the United States, Europe and Asia. As part of the Permanent Injunction, the Defendants have [Read More…]